secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0001437749-23-017353
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics holds virtual R&D Day; reviews platform and recent designations
--------------------------------------------------------------------------------

- Presented portfolio update including recent Breakthrough Therapy and Fast Track designations.
- Highlighted programs: influenza, C. diff, type 1 diabetes (SAB-176, SAB-185, SAB-142, SAB-195).
- No new financial guidance, clinical data, or material business changes disclosed.
- Presentation furnished as Exhibit 99.1 but not text-available; summary based on filing narrative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923017353/0001437749-23-017353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923017353/sabs20230609_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-017353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer